Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Lung Neoplasms 17Neoplasms 14Carcinoma 9Neoplasm Metastasis 7Thoracic Neoplasms 4NSCLC 4Colorectal Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Neoplasms by Site 3Lung Diseases 3Bronchial Neoplasms 3Brain Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Noonan Syndrome 2Neoplasms, Nerve Tissue 2Neoplasms by Histologic Type 2Meningeal Carcinomatosis 2Head and Neck Neoplasms 2Carcinoma, Bronchogenic 2Breast Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1T790M Positive NSCLC Patients 1Stomach Neoplasms 1

Interventions

pembrolizumab 75Carboplatin 46Paclitaxel 44130-nm albumin-bound paclitaxel 35Gemcitabine 34Cyclophosphamide 23Capecitabine 22Nivolumab 21Albumin-Bound Paclitaxel 21atezolizumab 20sacituzumab govitecan 14spartalizumab 13Doxorubicin 11olaparib 9Cisplatin 9Bevacizumab 9eribulin 8fludarabine 7durvalumab 7avelumab 7Injections 7Fulvestrant 7Fluorouracil 7Vinorelbine 6Leucovorin 6Docetaxel 6iniparib 5budigalimab 5Ipilimumab 5Epirubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Triple Negative Breast Neoplasms × osimertinib × Clear all
NCT06618287 2026-05-07

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Recruiting
416 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡